Lista de obras - Kenneth Marek - Dominio Público Uruguay

123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease

scientific article published on 04 October 2018

A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease

artículo científico publicado en 2017

A longitudinal program for biomarker development in Parkinson's disease: a feasibility study

artículo científico publicado en 2009

A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study

artículo científico publicado en 2014

A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease

artículo científico publicado en 2001

Abolishing the 1-year rule: How much evidence will be enough?

artículo científico publicado en 2016

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease

artículo científico publicado en 2013

Author Response

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort

artículo científico publicado en 2017

Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression

artículo científico publicado en 2008

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study

artículo científico publicado en 2016

Can we image premotor Parkinson disease?

artículo científico publicado en 2009

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease

artículo científico

Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging

artículo científico publicado en 2016

Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study

scientific article published on 19 February 2020

Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-up

artículo científico publicado en 2020

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

artículo científico publicado en 2019

Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.

artículo científico publicado en 2015

Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective

artículo científico publicado en 2016

Cognition and the course of prodromal Parkinson's disease.

artículo científico publicado en 2017

Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings

artículo científico publicado en 2015

Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person

scientific article published on 01 January 2020

Concordance for Parkinson's disease in twins: A 20-year update

artículo científico publicado en 2019

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort

artículo científico publicado en 2017

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease

artículo científico publicado en 1995

Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers

scientific article published on 01 June 2019

Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs

artículo científico publicado en 2019

Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits

artículo científico publicado en 2015

Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study

artículo científico publicado en 2007

Do dopamine agonists or levodopa modify Parkinson's disease progression?

artículo científico publicado en 2002

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.

artículo científico publicado en 2017

Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies

artículo científico publicado en 2003

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease

artículo científico publicado en 2012

Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder

artículo científico publicado en 2020

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

artículo científico publicado en 2004

Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease

artículo científico publicado en 2015

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

artículo científico publicado en 1999

Estimating the half-lives of PCB congeners in former capacitor workers measured over a 28-year interval

artículo científico

Evaluation of dosimetry, quantitative methods and test-retest variability of 18F-PI-2620 PET for the assessment of tau deposits in the human brain

scientific article published on 11 November 2019

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease

artículo científico publicado en 2020

FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients

artículo científico publicado en 2010

Fatigue in levodopa-naive subjects with Parkinson disease

artículo científico publicado en 2008

Finding useful biomarkers for Parkinson's disease

article

Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study

artículo científico publicado en 2014

Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa

artículo científico publicado en 2003

Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.

artículo científico publicado en 2012

Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging

artículo científico publicado en 2014

Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience

artículo científico publicado en 2020

Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans

artículo científico publicado en 2013

Levodopa and the progression of Parkinson's disease

artículo científico publicado en 2004

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.

artículo científico publicado en 2017

Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease

scientific article published on 30 July 2019

Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort

artículo científico publicado en 2018

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

artículo científico publicado en 2014

Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders ⬇️

artículo científico publicado el 31 de octubre de 2003

MDS clinical diagnostic criteria for Parkinson's disease

artículo científico publicado en 2015

MDS research criteria for prodromal Parkinson's disease

artículo científico publicado en 2015

Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease

scholarly article by Klaus Romero et al published May 2019 in Clinical and Translational Science

Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies

artículo científico publicado en 2011

Movement disorder society criteria for clinically established early Parkinson's disease

scholarly article by Daniela Berg et al published 25 August 2018 in Movement Disorders

Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease

artículo científico publicado en 2012

Novel recruitment strategy to enrich for LRRK2 mutation carriers

artículo científico publicado en 2015

Observations on a 2-Step Approach to Screening for Parkinson Disease-Reply

artículo científico publicado en 2017

Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging study

artículo científico publicado en 2010

Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients

artículo científico publicado en 2007

Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study

scientific article published on 27 April 2018

Portable objective assessment of upper extremity motor function in Parkinson's disease

artículo científico publicado en 2017

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

artículo científico publicado en 2013

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

artículo científico publicado en 2004

Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β.

scientific article published on 21 October 2015

Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures

scientific article published on 01 January 2019

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease

artículo científico publicado en 2016

Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study

artículo científico publicado en 2010

Reply: Unusual DAT scan results

artículo científico publicado en 2013

Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease

artículo científico publicado en 2007

Role of DAT-SPECT in the diagnostic work up of parkinsonism

artículo científico publicado en 2007

Serotonergic dysfunction in depression associated with Parkinson's disease

artículo científico publicado el 1 de septiembre de 1992

Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".

artículo científico publicado en 2011

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease

artículo científico publicado en 2008

Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease

artículo científico publicado en 2003

Striatal dopamine transporters correlate with simple reaction time in elderly subjects

artículo científico publicado en 2007

Supplement neuroimaging movement disorders

artículo científico publicado en 2009

T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN.

artículo científico publicado en 2018

Tau PET imaging with 18F-PI-2620 in patients with Alzheimer's disease and healthy controls: a first-in-human study

scientific article published on 11 November 2019

Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury.

artículo científico publicado en 2014

TechSight. Imaging. A molecular map for neurodegeneration

artículo científico publicado en 2000

The Effect of the COVID-19 Pandemic on People with Parkinson's Disease

artículo científico publicado en 2020

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort

scientific article published on 31 October 2018

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease

article published in 2019

The molecular basis of dopaminergic brain imaging in Parkinson's disease

artículo científico publicado el 1 de febrero de 2012

The natural history of the syndrome of primary progressive freezing gait

artículo científico publicado en 2002

The new definition and diagnostic criteria of Parkinson's disease

artículo científico publicado en 2016

The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease

artículo científico publicado en 2014

The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies

artículo científico publicado en 2017

The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease.

artículo científico publicado en 2005

The role of radiotracer imaging in Parkinson disease

artículo científico publicado en 2005

The role of the core imaging laboratory in multicenter trials

artículo científico publicado en 2010

The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study

artículo científico publicado en 2008

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease

artículo científico publicado en 2014

Traditional neuropsychological correlates and reliability of the automated neuropsychological assessment metrics-4 battery for Parkinson's disease

artículo científico publicado en 2012

Unique roles of SPET brain imaging in clinical and research studies. Lessons from Parkinson's disease research

artículo científico publicado en 2005

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

artículo científico publicado en 2017

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression

scientific article published on 15 August 2020

[(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy

artículo científico publicado en 2001

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease

artículo científico publicado en 1996

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

artículo científico publicado en 2001

[18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease

scientific article published on 28 June 2019

Lista de obras de Kenneth Marek

123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease

A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease

A longitudinal program for biomarker development in Parkinson's disease: a feasibility study

A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study

A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease

Abolishing the 1-year rule: How much evidence will be enough?

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease

Author Response

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort

Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study

Can we image premotor Parkinson disease?

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease

Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging

Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study

Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-up

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.

Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective

Cognition and the course of prodromal Parkinson's disease.

Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings

Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person

Concordance for Parkinson's disease in twins: A 20-year update

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease

Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers

Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs

Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits

Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study

Do dopamine agonists or levodopa modify Parkinson's disease progression?

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.

Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease

Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

Estimating the half-lives of PCB congeners in former capacitor workers measured over a 28-year interval

Evaluation of dosimetry, quantitative methods and test-retest variability of 18F-PI-2620 PET for the assessment of tau deposits in the human brain

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease

FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients

Fatigue in levodopa-naive subjects with Parkinson disease

Finding useful biomarkers for Parkinson's disease

Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study

Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa

Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.

Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging

Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience

Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans

Levodopa and the progression of Parkinson's disease

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.

Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease

Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders ⬇️

MDS clinical diagnostic criteria for Parkinson's disease

MDS research criteria for prodromal Parkinson's disease

Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease

Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies

Movement disorder society criteria for clinically established early Parkinson's disease

Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease

Novel recruitment strategy to enrich for LRRK2 mutation carriers

Observations on a 2-Step Approach to Screening for Parkinson Disease-Reply

Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging study

Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients

Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study

Portable objective assessment of upper extremity motor function in Parkinson's disease

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β.

Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease

Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study

Reply: Unusual DAT scan results

Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease

Role of DAT-SPECT in the diagnostic work up of parkinsonism

Serotonergic dysfunction in depression associated with Parkinson's disease

Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease